SVB Leerink Boosts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $33.00

Agios Pharmaceuticals (NASDAQ:AGIOGet Rating) had its price target upped by SVB Leerink to $33.00 in a research report issued on Tuesday, Stock Target Advisor reports. The brokerage presently has a “market perform” rating on the biopharmaceutical company’s stock. SVB Leerink’s price target indicates a potential upside of 49.12% from the company’s previous close.

Other analysts have also recently issued research reports about the stock. The Goldman Sachs Group dropped their price objective on shares of Agios Pharmaceuticals from $37.00 to $23.00 and set a “sell” rating on the stock in a report on Monday, March 7th. Royal Bank of Canada raised their target price on shares of Agios Pharmaceuticals from $61.00 to $67.00 and gave the company an “outperform” rating in a research note on Friday, February 25th. Canaccord Genuity Group lowered their target price on shares of Agios Pharmaceuticals from $52.00 to $44.00 and set a “buy” rating on the stock in a research note on Wednesday, February 16th. StockNews.com began coverage on shares of Agios Pharmaceuticals in a research note on Thursday, March 31st. They set a “sell” rating on the stock. Finally, Canaccord Genuity Group lowered their target price on shares of Agios Pharmaceuticals from $52.00 to $44.00 and set a “buy” rating on the stock in a research note on Wednesday, February 16th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Agios Pharmaceuticals currently has an average rating of “Hold” and an average target price of $51.57.

Shares of AGIO stock traded down $0.01 during trading hours on Tuesday, reaching $22.13. The stock had a trading volume of 3,968 shares, compared to its average volume of 742,946. Agios Pharmaceuticals has a twelve month low of $20.20 and a twelve month high of $62.15. The firm has a 50-day simple moving average of $26.72 and a 200-day simple moving average of $31.53. The firm has a market capitalization of $1.21 billion, a PE ratio of -3.43 and a beta of 1.51.

Agios Pharmaceuticals (NASDAQ:AGIOGet Rating) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.83) by $0.09. The firm had revenue of $0.83 million during the quarter, compared to analyst estimates of $2.71 million. During the same period last year, the business earned ($1.31) EPS. Analysts predict that Agios Pharmaceuticals will post -7.08 EPS for the current year.

Several large investors have recently bought and sold shares of the company. Farallon Capital Management LLC boosted its position in shares of Agios Pharmaceuticals by 6.1% during the 1st quarter. Farallon Capital Management LLC now owns 1,333,012 shares of the biopharmaceutical company’s stock valued at $38,804,000 after purchasing an additional 76,434 shares in the last quarter. Connacht Asset Management LP boosted its position in shares of Agios Pharmaceuticals by 35.3% during the 1st quarter. Connacht Asset Management LP now owns 9,648 shares of the biopharmaceutical company’s stock valued at $281,000 after purchasing an additional 2,515 shares in the last quarter. PDT Partners LLC bought a new position in shares of Agios Pharmaceuticals during the 1st quarter valued at about $939,000. State Street Corp boosted its position in shares of Agios Pharmaceuticals by 6.5% during the 1st quarter. State Street Corp now owns 3,186,513 shares of the biopharmaceutical company’s stock valued at $92,759,000 after purchasing an additional 193,631 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Agios Pharmaceuticals by 131.3% in the first quarter. Invesco Ltd. now owns 76,637 shares of the biopharmaceutical company’s stock worth $2,232,000 after buying an additional 43,504 shares during the period.

Agios Pharmaceuticals Company Profile (Get Rating)

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.

Read More

Stock Target Advisor logo

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.